Nestlé responds to industry trend with targeted GLP-1 products

USA- Nestlé, the world’s largest food and beverage company, has responded to the most disruptive food industry trend in the past few years by offering products targeted to GLP-1 users and creating a public platform for offering nutritional advice. 

According to a recent study by Morgan Stanley and CNBC, over 60% of GLP-1 users are spending less on restaurants, and this proportion continues to rise. Users are staying away from fast food, buying fewer items at supermarkets, eating fewer carbs, and drinking less coffee and sugar. 

Nestlé is among the first food companies to respond to this emerging trend.  

Steve Presley, Nestlé North America CEO said, “As the use of medications to support weight loss continues to rise, we see an opportunity to serve those consumers. We’re leveraging our deep understanding of consumers and nutritional science to stay ahead of the trends that are shaping consumer behaviours, and innovating across our portfolio to deliver products people will love.” 

The company announced the launch of the frozen Vital Pursuit product line in early June. The line includes offerings like sandwich melts, protein pastas, whole-grain bowls, and pizzas, all retailing at US$4.99. The new product line will reach retail outlets later in the year. 

The company revealed that an important aspect of its response to the current trend is pricing. The pricing strategy is meant to appeal to cash-strapped GLP-1 users looking for affordable and healthy products. A recent study revealed more than half of all weight loss medication users feel they are difficult to afford; a month’s supply of Ozempic costs around US$1,000. 

On July 1, Nestlé launched a website dedicated to providing valuable health information and nutritional support to customers on weight loss medication, a move intended to add value to customer experience.  

With around a third of Americans currently obese, semaglutide drugs have entered mainstream conversation, causing sales of GLP-1 drugs to increase over the years significantly. An estimated 1 in every 8 Americans, 30 million people, have tried an iteration of the weight loss drug.  

GLP-1 drugs like Wegovy, Ozempic, Mounjaro, and Zepbound promote weight loss, making users feel fuller and eat less, which has significantly changed the food industry.